CLiMB Study Highlights
The landmark CLiMB study has delivered compelling evidence that HelioLiver, a multi-analyte blood test developed by Helio Genomics, significantly outperforms ultrasound in detecting early-stage hepatocellular carcinoma (HCC), the most common form of liver cancer. Presented at major industry forums and published in peer-reviewed literature, the trial data demonstrated superior sensitivity in identifying HCC at its earliest and most treatable stages, particularly among patients with cirrhosis and other high-risk conditions who traditionally rely on ultrasound surveillance. The test analyzes cell-free DNA fragments in the blood, using artificial intelligence to detect cancer-specific molecular signatures that imaging alone frequently misses.
Also worth reading: What Are the Latest Liver Cancer Screening Guidelines and How Can AI Help You Benefit? · Do You Need Liver Monitoring When Taking Prednisone, and How Often Should Blood Tests Be Done? · Who Is Eligible for a Low-Dose CT Lung Cancer Screening Test in 2026?
For patients and clinicians, these findings could reshape standard screening protocols. Ultrasound, the long-standing surveillance standard, suffers from limited sensitivity, especially in patients with obese body habitus or nodular livers, leaving many early cancers undetected until advanced stages. A blood-based, AI-powered alternative offers a more accessible, reproducible, and accurate option that could be administered in routine clinical settings without specialized imaging expertise. As Helio Genomics advances regulatory and commercialization efforts, the CLiMB results position HelioLiver as a potential new standard for early HCC detection, offering hope for dramatically improved survival outcomes through earlier intervention.
Superior Sensitivity Rates
HelioLiver, a multi-analyte blood test developed by Helio Genomics, has demonstrated remarkable performance in the landmark CLiMB study, outperforming ultrasound for early detection of hepatocellular carcinoma (HCC), the most common form of liver cancer. The test analyzes cell-free DNA fragments in the blood, detecting characteristic methylation patterns and other molecular signatures released by tumor cells. In the CLiMB trial, HelioLiver achieved sensitivity rates substantially higher than ultrasound, particularly for early-stage disease where ultrasound alone often misses small lesions, especially in patients with cirrhosis or obesity whose body habitus complicates imaging. This advantage matters because HCC is frequently diagnosed at advanced stages, when treatment options are limited and survival rates drop dramatically.
The implications for clinical practice are significant. Current surveillance guidelines rely on ultrasound with or without alpha-fetoprotein testing, yet adherence remains poor and accuracy is inconsistent. A simple blood test could expand screening to at-risk populations, including those with hepatitis B, hepatitis C, and alcohol-related liver disease, while offering a more reliable option for patients where ultrasound performs poorly. As validation continues and regulatory pathways advance, HelioLiver may reshape how clinicians identify liver cancer at its most treatable stage, potentially improving outcomes for millions worldwide.
Multi-Analyte Technology
HelioLiver, developed by Helio Genomics, represents a meaningful shift in how hepatocellular carcinoma (HCC) may be detected before it advances. The test analyzes multiple analytes, including cell-free DNA fragments, using an artificial intelligence algorithm trained to recognize methylation patterns associated with early-stage liver cancer. Results from the landmark CLiMB study, presented at major hepatology forums and published in peer-reviewed literature, showed that HelioLiver achieved substantially higher sensitivity than ultrasound for detecting HCC at early stages, particularly among patients with cirrhosis or chronic hepatitis B where surveillance is most critical. Ultrasound, the current standard, misses a significant share of early tumors, especially in patients with obesity or nodular livers that obscure imaging.
The implications are considerable. Earlier and more accurate detection directly improves survival, since curative treatments like resection and ablation work best when tumors are small. A simple blood draw could expand surveillance to patients who lack access to imaging or who fall through screening gaps. While validation in broader populations and real-world adoption remain ongoing, the CLiMB data suggest AI-driven multi-analyte testing could become a powerful complement, and potentially an alternative, to ultrasound in liver cancer surveillance programs.
AI-Powered Precision
HelioLiver, a multi-analyte blood test developed by Helio Genomics, is generating significant attention following results from the landmark CLiMB study, which demonstrated superior sensitivity over ultrasound for early detection of hepatocellular carcinoma (HCC), the most common form of liver cancer. The test analyzes cell-free DNA fragments in the blood, using artificial intelligence to detect methylation patterns and other molecular signatures associated with early-stage tumors. In the CLiMB trial, HelioLiver substantially outperformed ultrasound, the current standard surveillance tool for at-risk patients, particularly in identifying stage I disease when treatment options are most effective and survival outcomes are dramatically better.
The implications for clinical practice are considerable. Ultrasound, while noninvasive and widely available, suffers from limited sensitivity, especially in patients with obesity or cirrhotic liver changes that obscure imaging. By contrast, HelioLiver offers an objective, reproducible molecular readout that could complement or, in some settings, replace imaging-based surveillance. As validation continues and regulatory pathways advance, this AI-driven approach may reshape early detection protocols, potentially reducing late-stage diagnoses and improving mortality rates among the millions of patients at elevated risk for liver cancer worldwide.
Commercial Partnership Impact
The CLiMB study results position HelioLiver as a commercially disruptive force in hepatocellular carcinoma screening, with the multi-analyte cell-free DNA blood test demonstrating superior sensitivity over ultrasound for early-stage detection. For healtho.io's partner ecosystem, this creates immediate opportunities across diagnostic laboratories, health systems, and payers seeking to modernize liver cancer surveillance programs. The at-risk population—cirrhosis patients and those with chronic hepatitis B—currently relies on ultrasound, which misses a substantial share of early tumors. A blood-based alternative removes barriers of operator dependency and body habitus limitations, expanding the addressable market for early detection services considerably.
Strategic partnerships will determine how quickly this advantage converts to market share. Health systems integrating HelioLiver into existing surveillance workflows can differentiate their oncology service lines while improving stage-at-diagnosis metrics that increasingly drive value-based reimbursement. Payers evaluating the test should weigh the cost of adoption against downstream savings from catching cancers at curable stages, when treatment options are less expensive and outcomes dramatically better. For AI healthcare consultants advising clients, the message is clear: early movers who secure distribution, integration, and reimbursement agreements around HelioLiver will define the competitive landscape in hepatology diagnostics for years ahead.
HelioLiver vs Ultrasound Performance
| Metric | HelioLiver (Blood Test) | Ultrasound |
|---|---|---|
| Early-stage HCC sensitivity | ~80% | ~45–63% |
| Detection method | Multi-analyte cell-free DNA | Imaging-based |
| Cirrhosis patient performance | High accuracy | Reduced by nodularity |
| Accessibility | Simple blood draw | Requires imaging expertise |